Abstract
Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.
| Original language | English |
|---|---|
| Title of host publication | Surgery in the Multimodal Management of Gastric Cancer |
| Publisher | Springer-Verlag Italia s.r.l. |
| Pages | 107-112 |
| Number of pages | 6 |
| Volume | 9788847023185 |
| ISBN (Print) | 9788847023185, 8847023173, 9788847023178 |
| DOIs | |
| Publication status | Published - Nov 1 2012 |
Fingerprint
Keywords
- Cytoreductive surgery
- Gastric cancer
- HIPEC
- Hyperthermia, induced
- Hyperthermic intraperitoneal chemotherapy
- Micrometastasis
- Molecular biology
- Peritoneal carcinomatosis
- Randomized controlled trials
- RT-PCR
- Surgical cytoreduction
- Surgical resection
ASJC Scopus subject areas
- Medicine(all)
Cite this
Hyperthermic intraperitoneal chemotherapy in gastric cancer : Indications and technical notes. / Mura, Gianni; Federici, Orietta; Garofalo, Alfredo.
Surgery in the Multimodal Management of Gastric Cancer. Vol. 9788847023185 Springer-Verlag Italia s.r.l., 2012. p. 107-112.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Hyperthermic intraperitoneal chemotherapy in gastric cancer
T2 - Indications and technical notes
AU - Mura, Gianni
AU - Federici, Orietta
AU - Garofalo, Alfredo
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.
AB - Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.
KW - Cytoreductive surgery
KW - Gastric cancer
KW - HIPEC
KW - Hyperthermia, induced
KW - Hyperthermic intraperitoneal chemotherapy
KW - Micrometastasis
KW - Molecular biology
KW - Peritoneal carcinomatosis
KW - Randomized controlled trials
KW - RT-PCR
KW - Surgical cytoreduction
KW - Surgical resection
UR - http://www.scopus.com/inward/record.url?scp=84930811520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930811520&partnerID=8YFLogxK
U2 - 10.1007/978-88-470-2318-5_15
DO - 10.1007/978-88-470-2318-5_15
M3 - Chapter
SN - 9788847023185
SN - 8847023173
SN - 9788847023178
VL - 9788847023185
SP - 107
EP - 112
BT - Surgery in the Multimodal Management of Gastric Cancer
PB - Springer-Verlag Italia s.r.l.
ER -